1. Bacus, J. W. et al. Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials. Cancer Epidemiol. Biomarkers Prev. 8, 1087–1094 (1999).
2. Kelloff, G. J. Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res. 78, 199–334 (2000).
3. Kelloff, G. J. et al. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin. Cancer Res. 10, 3881–3884 (2004).
4. Kelloff, G. J. et al. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol. Biomarkers Prev. 9, 127–137 (2000).
5. O'Shaughnessy, J. A. et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res. 8, 314–346 (2002). This article defines IEN, its clinical significance, and suggested clinical-trial designs of chemopreventive agents in nine target organs.